Mergers and innovation in big pharma

B-Tier
Journal: International Journal of Industrial Organization
Year: 2009
Volume: 27
Issue: 1
Pages: 70-79

Score contribution per author:

2.011 = (α=2.01 / 1 authors) × 1.0x B-tier

α: calibrated so average coauthorship-adjusted count equals average raw count

Abstract

The aims of this paper are to study the effects of mergers on the R&D activity of consolidated firms and to explore the relationship between ex-ante relatedness of merging parties and their ex-post performances. The analysis is conducted using data of the pharmaceutical industry for the period 1988-2004. The empirical results suggest that merged companies have on average, worse performances than the group of non-merging firms. This result is confirmed when I account for the endogeneous formation of mergers by selecting a control group first using the propensity score method and then taking into account the technological relatedness of the firms. Finally, I find that higher levels of technological relatedness are not associated with better R&D outcomes.

Technical Details

RePEc Handle
repec:eee:indorg:v:27:y:2009:i:1:p:70-79
Journal Field
Industrial Organization
Author Count
1
Added to Database
2026-01-26